Efficacy Outcomes from a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents

Background/Purpose: Newer migraine-specific preventive treatments targeting the calcitonin gene-related peptide (CGRP) pathway, such as fremanezumab, are approved for adults with chronic and episodic migraine (EM). However, data are lacking on the efficacy of CGRP pathway mAbs in children and adolescents. This study (NCT04458857) aimed to evaluate the efficacy, safety, and tolerability of fremanezumab for the preventive treatment of EM in children and adolescents. Here, we present efficacy outcomes.